ANVISA = EMA’s ABEL! [Regulatives / Guidelines]

posted by Lucas – Brazil, 2016-05-19 20:32 (3231 d 20:29 ago) – Posting: # 16336
Views: 11,476

Hi guys.

Earlybird is right. Anvisa is now suggesting the use of EMA's ABEL based on the 2014 WHO guideline. I've discussed with one of ANVISA's statistician and he said that this will probably be included in their own guidelines/resolutions soon. I showed him the thread we had here about TIE inflation but he said they were going to follow the 30% ISCV criteria anyway, because of WHO's guidance, abandoning the >40% "home brewed" criteria. Since it is not yet published as guidelines or resolutions we always submit the protocol for evaluation before initiating the study, even though the answer is always the same. The use of semi or partial replicated designs is also allowed, since blood volume might be a problem for 4-period studies.

Detlew:
As Mauricio said, there isn't a specific guideline determining the ANOVA structure for replicated designs, but I've always used FDA's suggestion (appendix E of 2001 guidance) without problems.

Hope I've been of help.

Lucas Teixeira

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,712 registered users;
29 visitors (0 registered, 29 guests [including 4 identified bots]).
Forum time: 16:02 CET (Europe/Vienna)

It’s easy to lie with statistics;
it is easier to lie without them.    Frederick Mosteller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5